When facing financial distress, avoid a "death by a thousand cuts." A single, deep reduction—even with an extra margin—is better. This prevents the cycle of fear and productivity decline that comes with repeated rounds of layoffs, allowing the remaining team to refocus on critical milestones needed for the next financing.
Getting an IPO done can require extreme measures. When IN8bio's banking syndicate hesitated due to market conditions, CEO William Ho called his largest investors to secure their commitment, fired the original banks, and gave the entire deal to a single, smaller firm (B. Riley) to push the IPO through.
A career on Wall Street can offer a unique advantage for biotech leadership. Unlike a pharma executive who might see only a few products through development, an analyst evaluates hundreds of companies. This builds an invaluable mental library of common failure modes and success patterns, enabling better strategic decisions.
Crossover rounds weren't a natural evolution. New Leaf Venture Partners created them out of necessity. After being denied significant allocations in hot biotech IPOs, they started investing privately just before the public offering to guarantee their participation and secure a larger stake.
Gamma-delta T-cells are not just another type of killer cell. They act as coordinators for the entire immune response, similar to a military JTAC (Joint Terminal Attack Controller). They bridge the innate and adaptive immune systems, identifying targets and calling in other specialized cells like a symphony conductor.
IN8bio's creation hinges on a chance event. A blizzard shut down New York City, canceling co-founder Dr. Lawrence Lamb's flight. This led to an impromptu meeting with future CEO William Ho, who then spent months researching the science before proposing they start a company together, highlighting the role of serendipity in innovation.
IN8bio chose glioblastoma, a difficult solid tumor, for a strategic reason: to de-risk their platform. By delivering the therapy directly to the brain post-surgery, they could bypass trafficking issues. This ensures that if the therapy fails, it's due to the mechanism itself, not because it didn't reach the target.
The hype around in-vivo CAR-T overlooks that it's a more complex form of gene therapy. It relies on the same delivery vectors (AAVs, LNPs) that have caused patient deaths and off-target effects like liver concentration in simpler gene therapies, suggesting a difficult path to success.